CStone expects 2026 pralesatinib capsule sales revenue to top CNY 300 million

PUBT · 2d ago
CStone expects 2026 pralesatinib capsule sales revenue to top CNY 300 million
  • CStone Pharmaceuticals forecast 2026 full-year sales revenue for RET inhibitor pralsetinib capsules to exceed CNY 300 million.
  • Outlook follows inclusion in China national reimbursement drug list effective Jan. 1, 2026.
  • Terminal sales volume rose more than 430% year over year through April 2026, driven by improved patient access under reimbursement.
  • First batch of domestically manufactured 100 mg pralsetinib capsules completed production and release, enabling nationwide commercial shipments.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260511-12154227), on May 11, 2026, and is solely responsible for the information contained therein.